RxDoctor Payments Data

Jeffrey Wessler, MD

Cardiovascular Disease · New York, NYNPI 1891053625

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,525 of the $11,294 with a category attached, or 75.5%. Janssen Scientific Affairs, LLC accounts for 75.5% of it on its own, with 3 other manufacturers making up the rest.

$11,294in general payments, 2019–2025

Across 14 payments — averaging $806.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$9K
  • Cleerly, Inc.$3K
  • Eli Lilly$106
  • AstraZeneca$40
$360,984in research payments, 2019–2025

Across 4 payments — averaging $90,246 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Withings, Inc.$361K

What the payments were for

  • Consulting fees$8,52575%
  • Food & beverage$2,76925%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Scientific Affairs, LLC9$8,525
Cleerly, Inc.2$2,623
Eli Lilly1$106
AstraZeneca2$40

How this compares

$11,294 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$91,319
Medicare patients
567
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metoprolol Succinate14$56

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →